Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

SAN FRANCISCO, CA and TOKYO--(Marketwire - Sep 30, 2012) - Medivation Inc. (MDVN) and Astellas Pharma Inc. (TSE: 4503) announced that new data for enzalutamide (XTANDI ® capsules), an oral ...

NEW YORK and TOKYO, May 29, 2020 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, P ...

With this approval, XTANDI is now the first and only oral treatment approved by the FDA in three distinct types of advanced prostate cancer – non-metastatic and metastatic castration-resistant ...

By weight, Xtandi is 65 times more expensive than gold. In the United States, that is 2.5 times the annual per capita income. In India, the name-brand drug costs more than 38 times the per capita ...